GlaxoSmithKline underwent a major corporate transformation, officially splitting its consumer healthcare division into a separate independent entity named Haleon while retaining the core GSK name to focus strictly on biopharmaceuticals and specialized vaccines. This strategic restructuring allowed the legacy pharmaceutical giant to streamline operations, concentrate research capital on high-value oncology and immunology pipelines, and resolve various historical legal overhangs.